ARSUF Fagron N.V.
OTCHealthcareAs of 2026-10-08 16:00
Why ARSUF matters now
Fagron N.V. (ARSUF) is a US stock in Healthcare. The latest InvestLog snapshot shows $25.80 with -6.18% on the session and $1.89B in market capitalization.
The latest indexable market news headline is "Fagron NV (ARSUF) Q3 2026 Sales/Trading Call Transcript" from Seeking Alpha.
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
BE
Exchange
OTC
Beta
0.39
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.